基于CXCR4表达的68Ga-Pentixafor PET/MRI评估中枢神经系统淋巴瘤
该前瞻性研究纳入7例中枢神经系统淋巴瘤患者,采用靶向CXCR4的新型示踪剂68Ga-Pentixafor PET/MRI进行病灶显示与疗效评估。结果显示PET检出18个病灶均经增强MRI证实,准确率100%,PTV41%与MRI肿瘤体积无显著差异,随访变化趋势一致。提示68Ga-Pentixafor PET可能用于CNSL的评估与随访。
要点
- 68Ga-Pentixafor PET检出18个CNSL病灶,全部经CE-MRI证实,准确率100%。
- PTV41%与VOLMRI无显著差异(平均差-0.24 cm,P=0.45),形态一致性最高。
- 随访中PTV41%变化趋势与VOLMRI一致,可反映病灶进展。
核心结论
- 68Ga-Pentixafor PET可能适用于中枢神经系统淋巴瘤的评估与随访。
主要发现
- 68Ga-Pentixafor PET检出18个病灶,均经CE-MRI证实,无假阳性,准确率100%。
- PTV41%与VOLMRI相比无显著差异(平均差-0.24 cm,P=0.45)。
- ADCmean与SUVmean41%呈中度相关(r=0.68)。
- 随访中PTV41%变化趋势与VOLMRI一致:患者1病灶进展(PTV41% +456.0%,VOLMRI +350.8%),患者3病灶进展(PTV41% +110.4%,VOLMRI +85.1%)。
关键数值与推荐
- 采用三种SUVmax阈值(41%、50%、70%)定义PTV(PTV41%、PTV50%、PTV70%),并用配对样本t检验与VOLMRI比较。
临床怎么用
- 68Ga-Pentixafor PET/MRI可作为CNSL病灶显示和随访的潜在工具,PTV41%或可用于肿瘤体积评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE OF THE REPORT: F-FDG PET is limited for assessment of central nervous system lymphoma (CNSL) due to physiologic tracer accumulation in the brain. We prospectively evaluated the novel PET tracer Ga-pentixafor, which targets the C-X-C chemokine receptor 4 (CXCR4), for lesion visualization and response assessment of CNSL. MATERIALS AND METHODS: Seven CNSL patients underwent Ga-pentixafor PET/MRI with contrast enhancement (CE-MRI) and diffusion-weighted sequences. The accuracy of Ga-pentixafor PET for CNSL lesion detection relative to the CE-MRI reference standard was determined. Standardized uptake values (SUVmean and SUVmax), PET-based (PTV) and MRI-based (VOLMRI) tumor volumes, and apparent diffusion coefficients (ADCs) were assessed, and correlation coefficients were calculated. Three SUVmax thresholds (41%, 50%, and 70%) were evaluated for PTV definitions (PTV41%, PTV50%, and PTV70%) and tested against VOLMRI using paired sample t tests. RESULTS: Twelve Ga-pentixafor PET/MRI examinations (including 5 follow-up scans) of 7 patients were evaluated. Ga-pentixafor PET demonstrated 18 lesions, all of which were confirmed by CE-MRI; there were no false-positive lesions on PET (accuracy, 100%). PTV41% showed the highest concordance with lesion morphology, with no significant difference compared with VOLMRI (mean difference, -0.24 cm; P = 0.45). The correlation between ADCmean and SUVmean41% (r = 0.68) was moderate. Changes in PTV41% on follow-up PET/MRI showed the same trend as VOLMRI changes, including progression of 1 lesion each in patient 1 (+456.0% PTV41% and +350.8% VOLMRI) and patient 3 (+110.4% PTV41% and +85.1% VOLMRI). CONCLUSIONS: Ga-pentixafor PET may be feasible for assessment and follow-up of CNSL. Future studies need to focus on testing its clinical value to distinguish between glioma and CNSL, and between radiation-induced inflammation and viable residual tumor.
引用
- Starzer AM, Berghoff AS, Traub-Weidinger T, et al. Assessment of Central Nervous System Lymphoma Based on CXCR4 Expression In Vivo Using 68Ga-Pentixafor PET/MRI. Clin Nucl Med. 2021. PMID: 33208624. doi:10.1097/RLU.0000000000003404
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。